SLC25A1 and cancer: In addition, targeting SLC25A1 revealed a susceptibility of cancer cells to inhibition of poly(ADP-ribose)-polymerase (PARP)1 or the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) in combination with IR, suggesting a window of therapeutic opportunity [12].